V-3579 Venetoclax, Free Base, >99%

Synonyms : [ABT-199] [GDC-0199] [RG7601]

Related Terms : [Venclexta]

  • Size
  • US $
  • £
  • ¥
  • 500 mg
  • 199
  • 183
  • 156
  • 31,000
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 249
  • 229
  • 195
  • 38,800
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 398
  • 366
  • 313
  • 62,000
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 880
  • 809
  • 692
  • 137,000
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 1,530
  • 1,407
  • 1,204
  • 238,200
  • Add to Cart Qty:
  • In stock
  • 20 g
  • 2,720
  • 2,502
  • 2,140
  • 423,400
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 868.44
  • C45H50ClN7O7S
  • [1257044-40-8]

Solubility: Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • More than 160 labs worldwide have purchased Venetoclax from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
  • Venetoclax, also known as ABT-199, is a BCL-2-selective inhibitor. It blocks the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of venetoclax in three patients with refractory chronic lymphocytic leukemia induced tumor lysis within 24 hours. Souers A.J., et al. "ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets." Nat. Med. 19: 202-208 (2013).
  • The high sensitivity to venetoclax was dependent on human multiple myeloma cell lines (HMCLs) with the CCND1 translocation. Six out of eight CCND1 cell lines were efficiently inhibited by venetoclax with a median LD50 value of 10 nM. Of note, the median venetoclax LD50 of sensitive HMCLs (10 nM) was significantly lower than that of peripheral blood lymphocytes from healthy donors (200 nM). Touzeau C., et al. "The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma." Leukemia 28: 210-212 (2014).
  • Both the BH3 mimetic venetoclax and phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors improved tumor responses to the antiestrogen tamoxifen in estrogen receptor-positive breast cancer. Vaillant F., et al "Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer." Cancer Cell 24: 120-129 (2013).
  • Venetoclax is the active ingredient in the drug product sold under the trade name Venclexta®   This drug is currently approved in a least one country for the treatment of adult patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma.  NOTE:  THE VENETOCLAX SOLD BY LC LABORATORIES FOR RESEARCH IS NOT VENCLEXTA®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.